Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.
This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.
Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.
A 1-year exercise intervention combining high-intensity interval training with resistance training may improve measures of cardiovascular risk among people with type 2 diabetes, suggests a secondary analysis of the D2FIT trial.
Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.
Full monitoring of biomedical and lifestyle-related diabetes target indicators is associated with significantly lower glycated hemoglobin levels than incomplete monitoring among people with type 2 diabetes in a care group setting, say researchers.
Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.
A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.
Measuring C-peptide in everyone a minimum of 3 years after a clinical diagnosis of type 1 diabetes can result in some people being reclassified with other forms of diabetes, researchers report.
Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.
Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.
Following the positive 2-year results of DiRECT, this symposium shared the first-hand experiences of a dietician, a general practitioner, and a person with diabetes who participated in the DiRECT study.
Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss diabetic retinopathy screening and the key role that it plays in reducing vision loss among people with diabetes (10:00).
